{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-25-000072","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.951167+00:00","generated_at":"2026-05-21T05:32:53.372878+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GRI Bio reports Q1 net loss $3.0M; GRI-0621 Phase 2a IPF trial on track for data in Q2/Q3 2025","bullets":["Net loss of $3.0M for Q1 2025; R&D expenses $1.6M, G&A $1.4M.","Cash $3.3M at March 31; subsequent $5M public offering; cash runway expected through Q3 2025.","Phase 2a trial of GRI-0621: 6-week interim data (n=24) expected Q2 2025; topline data Q3 2025.","Interim 2-week data in first 12 patients showed safety, no hyperlipidemia, and biomarker PRO-C3 suggestive of anti-fibrotic effect.","Enrollment over two-thirds complete for overall Phase 2a IPF trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-25-000072","json":"https://secwatch.observer/filing/0001824293-25-000072.json","markdown":"https://secwatch.observer/filing/0001824293-25-000072.md","text":"https://secwatch.observer/filing/0001824293-25-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429325000072/0001824293-25-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429325000072/val-20250515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:32:53.372878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}